The study of chimeric antigen receptor T (CAR-T) cell therapy in refractory/relapsed T-cell malignancies.
10.3760/cma.j.issn.0253-2727.2022.04.015
- Author:
Hu Jun LI
1
;
Kai Lin XU
1
Author Information
1. Blood Diseases Institute, Xuzhou Medical University; Department of Hematology, the Affiliated Hospital of Xuzhou Medical University; Key Laboratory of Bone Marrow Stem Cell, Xuzhou 221002, China.
- Publication Type:Journal Article
- MeSH:
Antigens, CD19;
Cell- and Tissue-Based Therapy;
Humans;
Immunotherapy, Adoptive;
Neoplasm Recurrence, Local;
Receptors, Antigen, T-Cell;
Receptors, Chimeric Antigen;
T-Lymphocytes
- From:
Chinese Journal of Hematology
2022;43(4):349-352
- CountryChina
- Language:Chinese
